Home > Products > Featured products

Pneumocandin B0

  Cat. No.:  DCAPI1447   Featured
Chemical Structure
135575-42-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Pneumocandin B0 is the major analogue of a family of lipopeptides isolated from several species of several different genera, notably Cryptosporiopsis, Glarea and Pezicula. Pneumocandin B0 is a potent antifungal and acts by inhibition of the synthesis of β
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 135575-42-7
Chemical Name: Pneumocandin B0
Synonyms: Pneumocandin B0;Pneumocardin B0;pneumocandin B(0);L-688786;PB0;B0 PneuMocandin B0;L 688786;pneumocandin Bo;1H-Dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacycloheneicosine,cyclic peptide deriv.;L-Proline, (4R,5R)-N2-[(10R,12S)-10,12-dimethyl-1-oxotetradecyl]-4,5-dihydroxy-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-3-hydroxy-,(6®1)-lactam, (3S)-;caspofungin intermediate;Caspofungin Pneumocandin B0 Impurity;N-[(3S,6S,11R,15S,18S,20R,21R,25S)-3-[(1R)-3-Amino-1-hydroxy-3-oxopropyl]-6-[(1S,2S)-1,2-dihydroxy-2;Caspofungin Pneumocandin B0;SCHEMBL10043973;N-[3-(3-Amino-1-hydroxy-3-oxopropyl)-6-[1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-(1-hydroxyethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide;135575-42-7;CHEBI:131609;(10R,12S)-N-((3S,6S,9S,11R,15S,18S,20R,21R,24S,25S)-3-((1R)-3-amino-1-hydroxy-3-oxopropyl)-6-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-11,20,21,25-tetrahydroxy-15-((1R)-1-hydroxyethyl)-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo(22.3.0.09,13)heptacosan-18-yl)-10,12-dimethyltetradecanamide;P2534;CHEMBL3037784;(10R,12S)-N-((2R,6S,9S,11R,12R,14aS,15S,20S,23S,25aS)-20-((1R)-3-amino-1-hydroxy-3-oxopropyl)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6-((1R)-1-hydroxyethyl)-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo(2,1-c:2',1'-l)(1,4,7,10,13,16)hexaazacyclohenicosin-9-yl)-10,12-dimethyltetradecanamide;L 688,786;Q27225219;UNII-BA795CZ3I2;(10R,12S)-N-((3S,6S,9S,11R,15S,18R,20R,21R,24S,25S)-6-((1S,2S)-1,2-Dihydroxy-2-(4-hydroxyphenyl)ethyl)-5,8,11,17,20,21,23,25-octahydroxy-3-((1R)-1-hydroxy-2-(C-hydroxycarbonimidoyl)ethyl)-15-((1R)-1-hydroxyethyl)-2,14-dioxo-1,4,7,13,16,22-hexaazatricyclo(22.3.0.0,)heptacosa-4,7,16,22-tetraen-18-yl)-10,12-dimethyltetradecanimidate;(10R,12S)-N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-10,12-dimethyltetradecanamide;Pneumocardin B(0);MFCD28168025;AKOS040758817;DA-56947;(10R,12S)-N-{(2R,6S,9S,11R,12R,14aS,15S,20S,23S,25aS)-20-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide;SCHEMBL8061793;L-PROLINE, (4R,5R)-N2-((10R,12S)-10,12-DIMETHYL-1-OXOTETRADECYL)-4,5-DIHYDROXY-L-ORNITHYL-L-THREONYL-(4R)-4-HYDROXY-L-PROLYL-(4S)-4-HYDROXY-4-(4-HYDROXYPHENYL)-L-THREONYL-(3R)-3-HYDROXY-L-GLUTAMINYL-3-HYDROXY-, (6->1)-LACTAM, (3S)-;Pneumocandin B(0...
SMILES: O([H])[C@@]1([H])C([H])([H])C([H])([H])N2C([C@]([H])([C@@]([H])(C([H])([H])C(N([H])[H])=O)O[H])N([H])C([C@]([H])([C@@]([H])([C@]([H])(C3C([H])=C([H])C(=C([H])C=3[H])O[H])O[H])O[H])N([H])C(C3([H])C([H])([H])[C@]([H])(C([H])([H])N3C([C@]([H])([C@@]([H])(C([H])([H])[H])O[H])N([H])C([C@]([H])(C([H])([H])[C@]([H])([C@]([H])(N([H])C(C21[H])=O)O[H])O[H])N([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])=O)=O)=O)O[H])=O)=O)=O
Formula: C50H80N8O17
M.Wt: 1065.2136
Purity: >99%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Pneumocandin B0(L-688786), a key intermediate in the synthesis of the antifungal agent, Cancidas, has led to the identification of several materials with potential for improved performance.
References: [1]. Welch CJ, et al. Preparation and evaluation of novel stationary phases for improved chromatographic purification of pneumocandin B0. J Chromatogr A. 2006 Jan 6;1101(1-2):204-13. [2]. Leonard WR Jr, et al. Synthesis of the antifungal beta-1,3-glucan synthase inhibitor CANCIDAS (caspofungin acetate) from pneumocandin B0. J Org Chem. 2007 Mar 30;72(7):2335-43.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DCAPI1451 Voriconazole Voriconazole is an ergosterol biosynthesis inhibitor, as well as systemic antifungal. This compound, like many antifungal agents, is an inhibitor of CYP2C9, an enzyme involved in the oxidative metabolism of many xenobiotics.
DCAPI1447 Pneumocandin B0 Pneumocandin B0 is the major analogue of a family of lipopeptides isolated from several species of several different genera, notably Cryptosporiopsis, Glarea and Pezicula. Pneumocandin B0 is a potent antifungal and acts by inhibition of the synthesis of β
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia